There are 1105 resources available
674P - Real-world outcomes of first-line platinum doublet chemotherapy plus Tyrosine Kinase Inhibitors (TKI) in advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC)
Presenter: Yi Fen Low
Session: Poster Display session
Resources:
Abstract
675P - Assessing later-line treatment strategies and outcomes in EGFR oncogene-driven stage IV non-small cell lung cancer
Presenter: Meghana Maddula
Session: Poster Display session
Resources:
Abstract
676P - NEJ053C: A phase II study of nivolumab and ipilimumab combined with chemotherapy after lung stereotactic body radiotherapy as first-line therapy for stage IV non-small cell lung cancer
Presenter: Kageaki Watanabe
Session: Poster Display session
Resources:
Abstract
677P - Comparison of performance of MET amplification detection by FISH, NGS and ddPCR in EGFRm advanced NSCLC patients post first-line osimertinib treatment failure: Analysis from a prospective, multi-center study in China
Presenter: Puyuan Xing
Session: Poster Display session
Resources:
Abstract
678P - Ramucirumab plus Erlotinib (RAM+ERL) for advanced non-small cell lung cancer (NSCLC) harboring EGFR L858R mutation (L858R mut): A multicenter retrospective observational cohort study (REAL-SPEED)
Presenter: Masashi Ishihara
Session: Poster Display session
Resources:
Abstract
679P - Low-dose durvalumab in combination with etoposide and platinum as first-line treatment of patients with extensive-stage small cell lung cancer: A multi-institutional study from India
Presenter: Vivek Agarwala
Session: Poster Display session
Resources:
Abstract
680P - Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: An exploratory analysis of initial AFA dosage in Gio-Tag Japan, a multicenter prospective observational study
Presenter: Akito Hata
Session: Poster Display session
Resources:
Abstract
681P - Characterising the genomic landscape of advanced non-squamous NSCLC of Chinese: A territory-wide study in Hong Kong
Presenter: Aya El-Helali
Session: Poster Display session
Resources:
Abstract
682P - First-line serplulimab for advanced squamous non-small cell lung cancer: A multicenter, single-arm, real-world ASTRUM-004R study
Presenter: Bo Shen
Session: Poster Display session
Resources:
Abstract
683P - Aumolertinib plus anlotinib in advanced EGFR-mutant NSCLC with brain metastasis (Alot BRAIN): A single-arm, phase II study (GASTO 1063) (updated data)
Presenter: Li Kun Chen
Session: Poster Display session
Resources:
Abstract